These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 32460015)

  • 1. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
    Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
    Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
    Mu P; Zhang Z; Benelli M; Karthaus WR; Hoover E; Chen CC; Wongvipat J; Ku SY; Gao D; Cao Z; Shah N; Adams EJ; Abida W; Watson PA; Prandi D; Huang CH; de Stanchina E; Lowe SW; Ellis L; Beltran H; Rubin MA; Goodrich DW; Demichelis F; Sawyers CL
    Science; 2017 Jan; 355(6320):84-88. PubMed ID: 28059768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
    Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss.
    Fan Y; Fan H; Quan Z; Wu X
    Cancer Invest; 2021 May; 39(5):423-434. PubMed ID: 33683975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
    Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
    Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
    Jiménez N; Garcia de Herreros M; Reig Ò; Marín-Aguilera M; Aversa C; Ferrer-Mileo L; García-Esteve S; Rodríguez-Carunchio L; Trias I; Font A; Rodriguez-Vida A; Climent MÁ; Cros S; Chirivella I; Domènech M; Figols M; Carles J; Suárez C; Herrero Rivera D; González-Billalabeitia E; Cívico C; Sala-González N; Ruiz de Porras V; Ribal MJ; Prat A; Mellado B
    Eur Urol Oncol; 2024 Aug; 7(4):954-964. PubMed ID: 38429210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
    Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
    Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
    Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
    BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    Iwasawa T; Kosaka T; Morita S; Mikami S; Nakamura K; Hongo H; Nishihara H; Oya M
    BMC Med Genomics; 2022 Jun; 15(1):138. PubMed ID: 35725469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Miao C; Tsujino T; Takai T; Gui F; Tsutsumi T; Sztupinszki Z; Wang Z; Azuma H; Szallasi Z; Mouw KW; Zou L; Kibel AS; Jia L
    Sci Adv; 2022 Feb; 8(7):eabl9794. PubMed ID: 35179959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
    Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
    Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation.
    Quintanal-Villalonga A; Kawasaki K; Redin E; Uddin F; Rakhade S; Durani V; Sabet A; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Kinyua D; Zhong H; Mello BP; Ciampricotti M; Bhanot UK; Linkov I; Qiu J; Patel RA; Morrissey C; Mehta S; Barnes J; Haffner MC; Socci ND; Koche RP; de Stanchina E; Molina-Pinelo S; Salehi S; Yu HA; Chan JM; Rudin CM
    Signal Transduct Target Ther; 2024 Jul; 9(1):189. PubMed ID: 39054323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling reveals the pivotal role of hrHPV driving copy number and gene expression alterations, including mRNA downregulation of TP53 and RB1 in penile cancer.
    Macedo J; Silva E; Nogueira L; Coelho R; da Silva J; Dos Santos A; Teixeira-Júnior AA; Belfort M; Silva G; Khayat A; de Oliveira E; Dos Santos AP; Cavalli LR; Pereira SR
    Mol Carcinog; 2020 Jun; 59(6):604-617. PubMed ID: 32212199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.